Compelling evidence supports the important role of the receptor in the activation of the advanced glycation end products axis (ADG) in multiple clinical entities. Since the onset of the 2019 coronavirus pandemic, concerns have been growing about the risk and management of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in inflammatory gastrointestinal disorders, such as inflammatory bowel disease (IBD).